Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward

Dexamethasone improves clinical outcomes in COVID-19 patients requiring supplementary oxygen. We investigated possible mechanisms of action by comparing sixteen plasma host response biomarkers in general ward patients before and after implementation of dexamethasone as standard of care. 48 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: de Brabander, Justin, Michels, Erik H. A., van Linge, Christine C. A., Chouchane, Osoul, Douma, Renée A., Reijnders, Tom D. Y., Schuurman, Alex R., van Engelen, Tjitske S. R., Wiersinga, W. Joost, van der Poll, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163524/
https://www.ncbi.nlm.nih.gov/pubmed/35659223
http://dx.doi.org/10.1186/s12931-022-02060-3
_version_ 1784719939962142720
author de Brabander, Justin
Michels, Erik H. A.
van Linge, Christine C. A.
Chouchane, Osoul
Douma, Renée A.
Reijnders, Tom D. Y.
Schuurman, Alex R.
van Engelen, Tjitske S. R.
Wiersinga, W. Joost
van der Poll, Tom
author_facet de Brabander, Justin
Michels, Erik H. A.
van Linge, Christine C. A.
Chouchane, Osoul
Douma, Renée A.
Reijnders, Tom D. Y.
Schuurman, Alex R.
van Engelen, Tjitske S. R.
Wiersinga, W. Joost
van der Poll, Tom
author_sort de Brabander, Justin
collection PubMed
description Dexamethasone improves clinical outcomes in COVID-19 patients requiring supplementary oxygen. We investigated possible mechanisms of action by comparing sixteen plasma host response biomarkers in general ward patients before and after implementation of dexamethasone as standard of care. 48 patients without and 126 patients with dexamethasone treatment were sampled within 48 h of admission. Endothelial cell and coagulation activation biomarkers were comparable. Dexamethasone treatment was associated with lower plasma interleukin (IL)-6 and IL-1 receptor antagonist levels, whilst other inflammation parameters were not affected. These data argue against modification of vascular-procoagulant responses as an early mechanism of action of dexamethasone in COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02060-3.
format Online
Article
Text
id pubmed-9163524
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91635242022-06-04 Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward de Brabander, Justin Michels, Erik H. A. van Linge, Christine C. A. Chouchane, Osoul Douma, Renée A. Reijnders, Tom D. Y. Schuurman, Alex R. van Engelen, Tjitske S. R. Wiersinga, W. Joost van der Poll, Tom Respir Res Correspondence Dexamethasone improves clinical outcomes in COVID-19 patients requiring supplementary oxygen. We investigated possible mechanisms of action by comparing sixteen plasma host response biomarkers in general ward patients before and after implementation of dexamethasone as standard of care. 48 patients without and 126 patients with dexamethasone treatment were sampled within 48 h of admission. Endothelial cell and coagulation activation biomarkers were comparable. Dexamethasone treatment was associated with lower plasma interleukin (IL)-6 and IL-1 receptor antagonist levels, whilst other inflammation parameters were not affected. These data argue against modification of vascular-procoagulant responses as an early mechanism of action of dexamethasone in COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02060-3. BioMed Central 2022-06-03 2022 /pmc/articles/PMC9163524/ /pubmed/35659223 http://dx.doi.org/10.1186/s12931-022-02060-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
de Brabander, Justin
Michels, Erik H. A.
van Linge, Christine C. A.
Chouchane, Osoul
Douma, Renée A.
Reijnders, Tom D. Y.
Schuurman, Alex R.
van Engelen, Tjitske S. R.
Wiersinga, W. Joost
van der Poll, Tom
Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward
title Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward
title_full Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward
title_fullStr Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward
title_full_unstemmed Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward
title_short Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward
title_sort association between dexamethasone treatment and the host response in covid-19 patients admitted to the general ward
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163524/
https://www.ncbi.nlm.nih.gov/pubmed/35659223
http://dx.doi.org/10.1186/s12931-022-02060-3
work_keys_str_mv AT debrabanderjustin associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT michelserikha associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT vanlingechristineca associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT chouchaneosoul associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT doumareneea associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT reijnderstomdy associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT schuurmanalexr associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT vanengelentjitskesr associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT wiersingawjoost associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward
AT vanderpolltom associationbetweendexamethasonetreatmentandthehostresponseincovid19patientsadmittedtothegeneralward

Ejemplares similares